GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » Gross-Profit-to-Asset %

Regenicin (Regenicin) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Regenicin Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Regenicin's annualized Gross Profit for the quarter that ended in Mar. 2023 was $0.00 Mil. Regenicin's average Total Assets over the quarter that ended in Mar. 2023 was $11.83 Mil. Therefore, Regenicin's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2023 was 0.00%.


Regenicin Gross-Profit-to-Asset % Historical Data

The historical data trend for Regenicin's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenicin Gross-Profit-to-Asset % Chart

Regenicin Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regenicin Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regenicin's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Regenicin's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenicin's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenicin's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Regenicin's Gross-Profit-to-Asset % falls into.



Regenicin Gross-Profit-to-Asset % Calculation

Regenicin's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Sep. 2022 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Sep. 2022 )/( (Total Assets (A: Sep. 2021 )+Total Assets (A: Sep. 2022 ))/ count )
=0/( (0.005+0.015)/ 2 )
=0/0.01
=0.00 %

Regenicin's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Mar. 2023 ))/ count )
=0/( (11.794+11.859)/ 2 )
=0/11.8265
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Regenicin Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Regenicin's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenicin (Regenicin) Business Description

Traded in Other Exchanges
N/A
Address
10 High Court, Little Falls, NJ, USA, 07424
Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.

Regenicin (Regenicin) Headlines

No Headlines